<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00052897</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02507</org_study_id>
    <secondary_id>AMC-035</secondary_id>
    <secondary_id>CDR0000258786</secondary_id>
    <nct_id>NCT00052897</nct_id>
  </id_info>
  <brief_title>SGN-00101 in Preventing Anal Cancer in Patients With HIV Who Have Anal Neoplasia</brief_title>
  <official_title>A Phase I/II Trial of SGN-00101 in the Treatment of High-Grade Anal Intraepithelial Neoplasia (AIN) in HIV-Positive Individuals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Phase I/II trial to study the effectiveness of SGN-00101 in preventing anal cancer in&#xD;
      HIV-positive patients who have high-grade anal neoplasia. Chemoprevention therapy is the use&#xD;
      of certain drugs to try to prevent the development of cancer. SGN-00101 may be effective in&#xD;
      preventing anal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Determine the safety and maximum tolerated dose of SGN-00101 in HIV-positive patients with&#xD;
      high-grade anal squamous intraepithelial lesions.&#xD;
&#xD;
      II. Determine clinical response and histologic/cytologic regression in patients treated with&#xD;
      this drug.&#xD;
&#xD;
      III. Determine immune response in patients treated with this drug. IV. Determine the effect&#xD;
      of this drug on HIV viral load and CD4 level in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study.&#xD;
&#xD;
      Patients receive SGN-00101 subcutaneously once on weeks 0, 4, and 8. Treatment continues in&#xD;
      the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 5-6 patients receive escalating doses of SGN-00101 until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose at which no more than 1 of 6&#xD;
      patients experience dose-limiting toxicity.&#xD;
&#xD;
      Patients are followed at 1, 4, and 10 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2002</start_date>
  <primary_completion_date type="Actual">July 2005</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Anal Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive SGN-00101 subcutaneously once on weeks 0, 4, and 8. Treatment continues in the absence of disease progression or unacceptable toxicity.&#xD;
Cohorts of 5-6 patients receive escalating doses of SGN-00101 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which no more than 1 of 6 patients experience dose-limiting toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HspE7</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed high-grade anal squamous intraepithelial lesions (HSIL) with&#xD;
             residual HSIL of the anal canal or margin by high-resolution anoscopy&#xD;
&#xD;
               -  Declined routine surgery or not a candidate for surgical excision of HSIL&#xD;
&#xD;
          -  Documented evidence of HIV infection by one of the following methods:&#xD;
&#xD;
               -  Serologic (ELISA or western blot)&#xD;
&#xD;
               -  Culture&#xD;
&#xD;
               -  Quantitative polymerase chain reaction or bDNA assays&#xD;
&#xD;
          -  HIV RNA no greater than 500 copies/mL&#xD;
&#xD;
          -  CD4 at least 200 x 10^6/L&#xD;
&#xD;
          -  Must have received stable highly active antiviral therapy (HAART) for at least 4 weeks&#xD;
             before study&#xD;
&#xD;
               -  HAART defined as 3 or more agents, including a protease inhibitor or&#xD;
                  nonnucleoside reverse transcriptase inhibitor that is approved or available&#xD;
                  through expanded access combination antiviral therapy&#xD;
&#xD;
          -  No prior history of invasive anal or cervical cancer&#xD;
&#xD;
          -  No concurrent untreated cervical HSIL&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 12 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Hemoglobin at least 10 g/dL&#xD;
&#xD;
          -  Platelet count at least 75,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  AST and ALT no greater than 3 times upper limit of normal (ULN)&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times ULN&#xD;
&#xD;
        Immunologic&#xD;
&#xD;
          -  No prior severe allergic reactions (i.e., anaphylactic response) to drugs or any other&#xD;
             allergen&#xD;
&#xD;
          -  No history of collagen-vascular or autoimmune disorder requiring treatment within the&#xD;
             past 5 years&#xD;
&#xD;
          -  No other concurrent illness that compromises the immune system&#xD;
&#xD;
          -  No active serious opportunistic infection&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use 2 forms of effective contraception during and for 3 months&#xD;
             after study&#xD;
&#xD;
          -  No concurrent participation in a conception process (e.g., active attempt to become&#xD;
             pregnant or impregnate, sperm donation, or in vitro fertilization)&#xD;
&#xD;
          -  No other concurrent medical or psychiatric illness that would preclude study&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No concurrent immunostimulants (including interferon or interleukin-12)&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  More than 1 year since prior chemotherapy for cancer&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No concurrent steroids that compromise immune function&#xD;
&#xD;
               -  Concurrent topical corticosteroids allowed if dose determined not to suppress&#xD;
                  immune function&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  More than 1 year since prior radiotherapy for cancer&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 30 days since other prior investigational agents&#xD;
&#xD;
          -  No concurrent medications that suppress immune function&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joel Palefsky, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2004</verification_date>
  <study_first_submitted>January 24, 2003</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>February 8, 2013</last_update_submitted>
  <last_update_submitted_qc>February 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>anal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anus Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

